1. Home
  2. DH vs AARD Comparison

DH vs AARD Comparison

Compare DH & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Definitive Healthcare Corp.

DH

Definitive Healthcare Corp.

SELL

Current Price

$1.00

Market Cap

112.1M

Sector

Technology

ML Signal

SELL

Logo Aardvark Therapeutics Inc.

AARD

Aardvark Therapeutics Inc.

BUY

Current Price

$3.78

Market Cap

97.4M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
DH
AARD
Founded
2011
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
112.1M
97.4M
IPO Year
2021
2025

Fundamental Metrics

Financial Performance
Metric
DH
AARD
Price
$1.00
$3.78
Analyst Decision
Hold
Buy
Analyst Count
7
11
Target Price
$1.90
★ $11.11
AVG Volume (30 Days)
★ 639.2K
107.3K
Earning Date
11-05-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 63.28
43.11
EPS
★ N/A
N/A
Revenue
★ $241,521,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.61
$3.35
52 Week High
$3.05
$16.60

Technical Indicators

Market Signals
Indicator
DH
AARD
Relative Strength Index (RSI) 57.38 28.18
Support Level $0.97 $3.38
Resistance Level $1.01 $5.88
Average True Range (ATR) 0.03 0.46
MACD -0.00 -0.11
Stochastic Oscillator 91.91 1.05

Price Performance

Historical Comparison
DH
AARD

About DH Definitive Healthcare Corp.

Definitive Healthcare Corp is a provider of healthcare commercial intelligence. Its SaaS-based healthcare commercial intelligence platform is designed to provide comprehensive and accurate information on the healthcare ecosystem in the U.S. The platform uses deep analytics and data science to help customers develop data-driven strategic decisions, such as finding new markets to enter, building comprehensive go-to-market strategies, accessing tactical information to help target the right decision makers, and improving win rates with detailed contextual information. The company derives substantially all of its revenue from the sale of subscription fees for access to its platform and stand-ready support. Geographically, it derives a majority of its revenue from the United States.

About AARD Aardvark Therapeutics Inc.

Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.

Share on Social Networks: